Insmed Incorporated
General ticker "INSM" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $30.6B (TTM average)
Insmed Incorporated does not follow the US Stock Market performance with the rate: -10.5%.
Estimated limits based on current volatility of 2.6%: low 105.45$, high 111.12$
Factors to consider:
- Total employees count: 1664 (+30.9%) as of 2025
- US accounted for 70.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Supply chain disruptions, Labor/talent shortage/retention, Cybersecurity threats, Liquidity and credit risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [91.28$, 206.47$]
- 2026-12-31 to 2027-12-31 estimated range: [61.00$, 147.88$]
Financial Metrics affecting the INSM estimates:
- Negative: with PPE of -27.6 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.17 > -0.60
- Positive: 19.19 < Shareholder equity ratio, % of 32.63 <= 42.57
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.22 <= 0.74
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 0.76
- Negative: Industry operating profit margin (median), % of -8.30 <= 2.87
Short-term INSM quotes
Long-term INSM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $305.21MM | $363.71MM | $606.42MM |
| Operating Expenses | $1,014.83MM | $1,241.96MM | $1,853.19MM |
| Operating Income | $-709.63MM | $-878.25MM | $-1,246.77MM |
| Non-Operating Income | $-37.39MM | $-31.81MM | $-24.98MM |
| Interest Expense | $81.69MM | $84.91MM | $83.80MM |
| R&D Expense | $571.01MM | $598.37MM | $771.09MM |
| Income(Loss) | $-747.01MM | $-910.07MM | $-1,271.75MM |
| Taxes | $2.56MM | $3.71MM | $5.03MM |
| Net Income(Loss)* | $-749.57MM | $-913.77MM | $-1,276.78MM |
| Stockholders Equity | $-331.92MM | $285.38MM | $738.98MM |
| Inventory | $83.25MM | $98.58MM | $132.07MM |
| Assets | $1,329.84MM | $2,025.23MM | $2,264.56MM |
| Operating Cash Flow | $-536.25MM | $-683.88MM | $-935.01MM |
| Capital expenditure | $13.29MM | $21.92MM | $32.56MM |
| Investing Cash Flow | $-223.60MM | $-583.17MM | $-64.58MM |
| Financing Cash Flow | $168.44MM | $1,341.02MM | $954.07MM |
| Earnings Per Share** | $-5.34 | $-5.57 | $-5.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.